Clinical Trial

A Study of GC101 TIL in Advanced Hepatobiliary-Pancreatic Cancers (10hospital)

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced hepatobiliary-pancreatic cancers. Autologous TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2021-10-26; most recent amendment 2025-12-04.
Trial Details
NCT Number NCT05098197
Lead Sponsor Shanghai Juncell Therapeutics
Collaborators: Shanghai 10th People's Hospital
Conditions Advanced Liver Cancers, Tumor Infiltrating Lymphocyte, Treatment Side Effects, Effects of Immunotherapy, Advanced Pancreatic Cancers
Enrollment 50 participants
Start Date 2021-09-26
Primary Completion 2026-09-25 (estimated)
Study Completion 2026-09-25 (estimated)
Updated on ClinicalTrials.gov 2025-12-11